RxDoctor Payments Data

Dawn Delaney

Family · East Norriton, PANPI 1346716826

Payments from drug & device makers

$7,941in general payments, 2019–2025

Across 424 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$968
  • Lilly USA, LLC$588
  • AstraZeneca$552
  • Sumitomo Pharma America, Inc.$381
  • Pfizer$360
  • plus $4K from 48 others

What the payments were for

  • Food & beverage$7,941100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,941 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$127,611
Medicare patients
479
Services billed
1,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$26,785
OzempicSemaglutide14$16,646
FarxigaDapagliflozin Propanediol22$14,629
GemtesaVibegron22$13,150
JardianceEmpagliflozin16$13,003
LinzessLinaclotide16$8,832
JanuviaSitagliptin Phosphate14$7,519
XareltoRivaroxaban22$5,678
Pregabalin57$4,242
BrilintaTicagrelor18$4,068
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,572
Buprenorphine15$3,240
Memantine Hcl23$2,313
Dorzolamide-TimololDorzolamide/Timolol/Pf16$1,967
Duloxetine Hcl46$1,878

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$360$26,78561 claims
AstraZenecaFarxiga, Brilinta$552$18,69740 claims
Novo NordiskOzempic$968$16,64614 claims
Sumitomo Pharma America, Inc.Gemtesa$381$13,15022 claims
Boehringer IngelheimJardiance$230$13,00316 claims
AbbVieLinzess$1,118$8,83216 claims
MerckJanuvia$108$7,51914 claims
Johnson & JohnsonXarelto$99$5,67822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in East Norriton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →